![](https://www.biopharmadive.com/imgproxy/rqA6wHWsLSJKPZEy9oQdU_6o0dwEaK0mJPavNQLDZ_8/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODc1MDQyMzAuanBn.jpg)
Comanche Biopharma raises $75M to fund preeclampsia drug testing
Dive Brief: Massachusetts-based startup Comanche BioPharma has raised $75 million in new venture funding to advance an experimental treatment targeting
Read MoreJuly 7, 2024
Dive Brief: Massachusetts-based startup Comanche BioPharma has raised $75 million in new venture funding to advance an experimental treatment targeting
Read MoreThe Food and Drug Administration on Tuesday approved Vertex Pharmaceuticals’ CRISPR-based medicine Casgevy for the inherited blood condition beta thalassemia, expanding
Read MoreGuarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market
Read MoreOver the span of five months, biotechnology startup Aiolos Bio launched, raised initial funding from venture investors and negotiated a
Read MoreThe J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For
Read MoreDive Brief: The use of GLP-1-based drugs to treat obesity and diabetes has no “clear relationship” with the risk of
Read MoreChris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. At a
Read MoreA group of high-profile scientists and billionaire financiers are building a new biomedical research institute that they claim will offer
Read MoreEuropean regulators will seek outside advice before making a decision on approval of Eisai and Biogen’s Leqembi medicine for Alzheimer’s
Read MoreDive Brief: The number and amount of biotechnology financings dipped in 2023, with venture firms investing 25% fewer dollars in
Read More